Benefits from Standalone Durvalumab Treatment in an Elderly Patient with Advanced Prostatic Sarcoma: a Case Report

Overview

Journal Transl Androl Urol

Date 2022 Jan 5

PMID 34984194

Authors

Lili Wang

Lei Wang

Dingkun Hou

Shiqiang Dong

Aixiang Wang

Haitao Wang

Affiliations

Soon will be listed here.

Abstract

There is a lacking of effective therapeutic strategies in the treatment of advanced prostatic sarcoma with high-frequency microsatellite instability (MSI-H) or mismatch repair deficient (dMMR). In this study, we present the first described a case of advanced MSI-H and dMMR prostatic sarcoma in elderly patients with multiple comorbidities, who received an anti-PD-L1 monoclonal antibody (durvalumab) as the first-line treatment and achieved partial remission (PR) without visible adverse events. A 91-year-old male patient presented with frequent urination and defecation difficulty for over three months, aggravating for ten days. Digital rectal examination showed the prostate gland was III° enlargement and tough with a smooth surface. The MRI showed occupying lesions in the prostate without distant metastasis. Then, the prostate biopsy showed poorly differentiated small round cell malignant tumor and considered prostatic sarcoma. Immunohistochemistry showed MSI-H and dMMR prostatic sarcoma. Durvalumab alone was applied at a cycle of every 21 days (500 mg/day) for 18 months and achieved PR two months since the treatment. During the treatment, we didn't observe rash, immune-related pneumonia, hepatitis, and other adverse events. Also, no recurrence or metastasis was observed until now. Durvalumab is effective and safe in the treatment of advanced MSI-H or dMMR prostatic sarcoma in an elderly patient. It is promising to be an available choice for advanced prostate sarcoma, which is unsuitable for surgery, conventional chemotherapy, and radiotherapy.

References

Karzai F, VanderWeele D, Madan R, Owens H, Cordes L, Hankin A . Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer. 2018; 6(1):141. PMC: 6280368. DOI: 10.1186/s40425-018-0463-2. View

Murakami Y, Tabata K, Sugita A, Mochizuki K, Maeyama R, Okazaki M . Multidisciplinary treatment including systemic chemotherapy for a malignant phyllodes tumour of the prostate. Can Urol Assoc J. 2014; 8(3-4):E263-5. PMC: 4001657. DOI: 10.5489/cuaj.1648. View

Smith M, Ridgway P, Catton C, Cannell A, OSullivan B, Mikula L . Combined management of retroperitoneal sarcoma with dose intensification radiotherapy and resection: long-term results of a prospective trial. Radiother Oncol. 2014; 110(1):165-71. DOI: 10.1016/j.radonc.2013.10.041. View

Lerrer S, Mor A . Immune checkpoint inhibitors and the shared epitope theory: from hypothesis to practice. Transl Cancer Res. 2021; 8(Suppl 6):S625-S627. PMC: 7928436. DOI: 10.21037/tcr.2019.07.43. View

Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D . Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. J Clin Oncol. 2018; 37(4):286-295. PMC: 6553803. DOI: 10.1200/JCO.18.00283. View

Musser J, Assel M, Mashni J, Sjoberg D, Russo P . Adult prostate sarcoma: the Memorial Sloan Kettering experience. Urology. 2014; 84(3):624-8. PMC: 4678959. DOI: 10.1016/j.urology.2014.05.036. View

Stewart R, Morrow M, Hammond S, Mulgrew K, Marcus D, Poon E . Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015; 3(9):1052-62. DOI: 10.1158/2326-6066.CIR-14-0191. View

Santoni M, Montironi R, Battelli N . Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018; 379(1):91-2. DOI: 10.1056/NEJMc1805988. View

Ohguri T, Imada H, Kato F, Yahara K, Morioka T, Nakano K . Radiotherapy with 8 MHz radiofrequency-capacitive regional hyperthermia for pain relief of unresectable and recurrent colorectal cancer. Int J Hyperthermia. 2006; 22(1):1-14. DOI: 10.1080/02656730500381152. View

10.

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

11.

Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

12.

Abbas S, Hill A . Prostatic sarcoma after treatment of rectal cancer. World J Surg Oncol. 2007; 5:82. PMC: 1950882. DOI: 10.1186/1477-7819-5-82. View

13.

De Bari B, Stish B, Ball M, Habboush Y, Sargos P, Krengli M . Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study. Prostate. 2017; 77(10):1160-1166. DOI: 10.1002/pros.23375. View

14.

Wang X, Liu L, Tang H, Rao Z, Zhan W, Li X . Twenty-five cases of adult prostate sarcoma treated at a high-volume institution from 1989 to 2009. Urology. 2013; 82(1):160-5. DOI: 10.1016/j.urology.2013.01.034. View

15.

Postow M, Callahan M, Wolchok J . Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015; 33(17):1974-82. PMC: 4980573. DOI: 10.1200/JCO.2014.59.4358. View

16.

Hicks N, Gurung P, Deshmukh N, Apakama I, Patel P . Primary prostate sarcoma: how to manage following diagnosis at transurethral resection. J Surg Case Rep. 2016; 2016(5). PMC: 4855216. DOI: 10.1093/jscr/rjw065. View

17.

Sharma P, Allison J . The future of immune checkpoint therapy. Science. 2015; 348(6230):56-61. DOI: 10.1126/science.aaa8172. View

18.

Welz S, Hehr T, Lamprecht U, Scheithauer H, Budach W, Bamberg M . Thermoradiotherapy of the chest wall in locally advanced or recurrent breast cancer with marginal resection. Int J Hyperthermia. 2005; 21(2):159-67. DOI: 10.1080/02656730400003393. View